BJH - volume 7, issue Abstract Book BHS, january 2016
J. Muller MSc, M. Binsfeld , S. Dubois , G. Carmeliet , Y. Beguin MD, PhD, R. Heusschen PhD, J. Caers MD, PhD
BJH - volume 7, issue Abstract Book BHS, january 2016
G. Fransolet , G. Ehx , J. Somja MD, PhD, L. Delens , M. Hannon , S. Dubois , P. Drion , J. Caers MD, PhD, S. Humblet-Baron , L. Belle , P. Delvenne , Y. Beguin MD, PhD, G. Conteduca , prof. F. Baron
BJH - volume 7, issue Abstract Book BHS, january 2016
R. Heusschen PhD, J. Muller MSc, M. Binsfeld , E. Plougonven , N. Mahli , G. Carmeliet , A. Léonard , prof. F. Baron , M. Cohen-Solal , K. Vanderkerken PhD, Y. Beguin MD, PhD, E. Menu , J. Caers MD, PhD
BJH - volume 6, issue 5, december 2015
K. Beel MD, PhD, M-C. Vekemans MD, G. Bries MD, PhD, J. Caers MD, PhD, B. De Pryck MD, K. Fostier MD, A. Kentos MD, PhD, N. Meuleman MD, PhD, P. Mineur MD, I. Van de Broek MD, PhD, K.L. Wu MD, PhD, C. Doyen MD, PhD, M. Delforge MD, PhD
Immunoglobulin light chain amyloidosis is a clonal plasma cell dyscrasia, historically associated with a very poor prognosis. Prompt diagnosis is critical to preserve organ function and improve survival in immunoglobulin light chain amyloidosis patients. The severity of cardiac involvement and response to treatment are the most important prognostic factors. Serum free light chain ratio and cardiac biomarkers troponin T and N-terminal pro-brain natriuretic peptide are powerful tools for the evaluation of prognosis and treatment response. Historically, treatment with autologous stem cell transplantation appears to offer a survival benefit, but is only an option in a minority of patients. IMiDs, and especially proteasome inhibitors, have shown promising activity in immunoglobulin light chain amyloidosis. Supportive care should be integrated in the treatment plan and requires a multidisciplinary approach. These guidelines summarise a consensus of the myeloma subcommittee of the Belgian Hematological Society on diagnosis, cytoreductive and supportive treatment of immunoglobulin light chain amyloidosis, based on an extended review of the literature. Where applicable, comments were added with respect to the Belgian reimbursement modalities.
(BELG J HEMATOL 2015;6(5):187–94)
Read moreBJH - volume 6, issue Abstract Book BHS, january 2015
M. Binsfeld , M. Hannon , S. Humblet-Baron , Y. Beguin MD, PhD, prof. F. Baron , J. Caers MD, PhD
BJH - volume 6, issue Abstract Book BHS, january 2015
J. Muller MSc, M. Binsfeld , S. Dubois , G. Carmeliet , Y. Beguin MD, PhD, R. Heusschen PhD, J. Caers MD, PhD
BJH - volume 5, issue 4, december 2014
M-C. Vekemans MD, K. Beel MD, PhD, J. Caers MD, PhD, N. Meuleman MD, PhD, G. Bries MD, PhD, V. Delrieu MD, H. Demuynck MD, B. De Prijck MD, H. De Samblanx MD, A. Deweweire MD, A. Kentos MD, PhD, P. Mineur MD, F. Offner MD, PhD, I. Vande Broek MD, PhD, A. Vande Velde MD, J. Van Droogenbroeck MD, KL. Wu MD, PhD, C. Doyen MD, PhD, R. Schots MD, PhD, M. Delforge MD, PhD
With the introduction of immunomodulatory drugs and proteasome inhibitors, major improvements have been achieved in the treatment and prognosis of multiple myeloma. Different treatment combinations are now in use and innovative therapies are being developed. This rapidly changing therapeutic landscape calls for an update on the Belgian myeloma guidelines, published in 2010.1 Based on an extensive review of the recent literature, the myeloma study group of the Belgian Hematology Society has revised the consensus recommendations on myeloma care, to be used by haematologists as a reference for daily practice. When applicable, comments with regards to the Belgian reimbursement modalities are included. The full text with appendices can be downloaded from the Belgian Hematology Society website (www.bhs.be) and from the Belgium Journal of Hematology website (www.ariez.com).
(BELG J HEMATOL 2014;5(4):125–36)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
